EcoDrugPlus

Phosphodiesterase 4b

Ensembl ID : ENSMZEG00005018432
Gene Symbol: PDE4B
3 Cross references
227 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSMZEG00005009333
Gene Symbol: PDE4B
3 Cross references
224 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSMZEG00005005989
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSMZEG00005021791
Gene Symbol: PDE7A
3 Cross references
227 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSMZEG00005015508
Gene Symbol: PDE7B
4 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSMZEG00005013723
Gene Symbol: PDE9A
1 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSMZEG00005005825
Gene Symbol: PIK3R1
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSMZEG00005016715
Gene Symbol: PIK3R2
3 Cross references
191 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSMZEG00005003704
Gene Symbol: PIK3R2
3 Cross references
189 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSMZEG00005017674
Gene Symbol: PIK3R3
3 Cross references
171 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSMZEG00005004332
Gene Symbol: PIK3R5
4 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSMZEG00005023924
Gene Symbol: PIK3R5
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).